TME Pharma

Executive Summary

TME Pharma is a German clinical-stage biotechnology company developing novel therapies targeting the tumor microenvironment (TME). Its lead candidate, NOX-A12, is a CXCL12 inhibitor designed to disrupt tumor protection barriers and enhance the efficacy of standard treatments like radiotherapy and anti-VEGF therapy. The company is currently evaluating NOX-A12 in combination with radiotherapy for newly diagnosed glioblastoma and in pancreatic cancer. Early clinical data have shown encouraging signals of improved tumor control and potential synergy with immune checkpoint inhibitors. TME Pharma's approach addresses the critical need for effective treatments in aggressive cancers with poor prognoses. The company is privately held and has been advancing its pipeline through strategic collaborations and academic partnerships. With a strong scientific foundation and a clear focus on TME modulation, TME Pharma represents an interesting opportunity in the oncology space, albeit at an early clinical stage.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data readout for NOX-A12 in glioblastoma40% success
• Q2 2027Initiation of Phase 2 trial for NOX-A12 in pancreatic cancer50% success
• TBDPotential partnership or licensing deal for NOX-A1230% success